FibroGen, Inc. has received a $6.4 million payment from AstraZeneca Treasury Limited, completing the first holdback outlined in the share purchase agreement related to the sale of FibroGen's China operations. The agreement, initially executed on February 20, 2025, saw FibroGen sell its China business through FibroGen International (Hong Kong) Ltd. to AstraZeneca for a total consideration of approximately $220 million. The latest payment includes $6.0 million from the initial holdback, released after final net cash adjustments, and an additional $0.4 million following these adjustments. A remaining $4.0 million holdback is set to be released, net of any indemnity claims, nine months after the closing.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FibroGen Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-269529), on November 06, 2025, and is solely responsible for the information contained therein.